Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02486718 · OUTCOME

Minimum Serum Concentration (Cmin) at Steady-State Within a Dosing Interval of Atezolizumab

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] · Source last updated 2026-07-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
μg/ml
Interval / dispersion
Geometric Coefficient of Variation
Time frame
Prior to infusion on Day 1 of Cycles 1, 2, 3, 4, 8, 16 (Cycle length = 21 days), at study discontinuation visit (up to 12 months), Day 120 post last dose of atezolizumab (up to 16 months)

Analysis population: PK-evaluable population was defined as all randomized participants who received any dose of the study treatment and who have evaluable pharmacokinetic samples. Number analyzed is the number of participants with data available for analyses at the specified timepoints.

Groups in this outcome

Atezolizumab

Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Atezolizumab493

Reported measurements

Cycle 1 Day 1

Analysis denominator · Participants

GroupSource count
Atezolizumab451
Values in μg/ml · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Atezolizumab367123.5Not reportedNot reportedNot reported
Cycle 2 Day 1

Analysis denominator · Participants

GroupSource count
Atezolizumab446
Values in μg/ml · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Atezolizumab87.879.3Not reportedNot reportedNot reported
Cycle 3 Day 1

Analysis denominator · Participants

GroupSource count
Atezolizumab436
Values in μg/ml · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Atezolizumab14158.4Not reportedNot reportedNot reported
Cycle 4 Day 1

Analysis denominator · Participants

GroupSource count
Atezolizumab419
Values in μg/ml · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Atezolizumab17057.6Not reportedNot reportedNot reported
Cycle 8 Day 1

Analysis denominator · Participants

GroupSource count
Atezolizumab353
Values in μg/ml · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Atezolizumab22240.6Not reportedNot reportedNot reported
Cycle 16 Day 1

Analysis denominator · Participants

GroupSource count
Atezolizumab300
Values in μg/ml · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Atezolizumab22187.3Not reportedNot reportedNot reported
Treatment Discontinuation Visit

Analysis denominator · Participants

GroupSource count
Atezolizumab404
Values in μg/ml · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Atezolizumab148221.8Not reportedNot reportedNot reported
Day 120 Post Last Dose of Atezolizumab

Analysis denominator · Participants

GroupSource count
Atezolizumab352
Values in μg/ml · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Atezolizumab8.58794.8Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        123.5
        value
        367
    denoms
    1. counts
      1. group Id
        OG000
        value
        451
      units
      Participants
    title
    Cycle 1 Day 1
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        79.3
        value
        87.8
    denoms
    1. counts
      1. group Id
        OG000
        value
        446
      units
      Participants
    title
    Cycle 2 Day 1
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        58.4
        value
        141
    denoms
    1. counts
      1. group Id
        OG000
        value
        436
      units
      Participants
    title
    Cycle 3 Day 1
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        57.6
        value
        170
    denoms
    1. counts
      1. group Id
        OG000
        value
        419
      units
      Participants
    title
    Cycle 4 Day 1
  5. categories
    1. measurements
      1. group Id
        OG000
        spread
        40.6
        value
        222
    denoms
    1. counts
      1. group Id
        OG000
        value
        353
      units
      Participants
    title
    Cycle 8 Day 1
  6. categories
    1. measurements
      1. group Id
        OG000
        spread
        87.3
        value
        221
    denoms
    1. counts
      1. group Id
        OG000
        value
        300
      units
      Participants
    title
    Cycle 16 Day 1
  7. categories
    1. measurements
      1. group Id
        OG000
        spread
        221.8
        value
        148
    denoms
    1. counts
      1. group Id
        OG000
        value
        404
      units
      Participants
    title
    Treatment Discontinuation Visit
  8. categories
    1. measurements
      1. group Id
        OG000
        spread
        794.8
        value
        8.58
    denoms
    1. counts
      1. group Id
        OG000
        value
        352
      units
      Participants
    title
    Day 120 Post Last Dose of Atezolizumab
denoms
  1. counts
    1. group Id
      OG000
      value
      493
    units
    Participants
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.
    id
    OG000
    title
    Atezolizumab
param Type
GEOMETRIC_MEAN
population Description
PK-evaluable population was defined as all randomized participants who received any dose of the study treatment and who have evaluable pharmacokinetic samples. Number analyzed is the number of participants with data available for analyses at the specified timepoints.
reporting Status
POSTED
time Frame
Prior to infusion on Day 1 of Cycles 1, 2, 3, 4, 8, 16 (Cycle length = 21 days), at study discontinuation visit (up to 12 months), Day 120 post last dose of atezolizumab (up to 16 months)
title
Minimum Serum Concentration (Cmin) at Steady-State Within a Dosing Interval of Atezolizumab
type
SECONDARY
unit Of Measure
μg/ml

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice